eLetters

117 e-Letters

published between 2010 and 2013

  • Response to: Five Factors Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use?
    Loic Guillevin

    Dear Editor,

    Moiseev and Novikov's comments on the Five-Factor Score (FFS) for eosinophilic granulomatosis with polyangiitis (EGPA) provide the opportunity to address the contribution of scores and their use. The FFS was designed to evaluate necrotizing vasculitis prognosis and identify manifestations associated with death: those are its only roles. Its strength is its validation on 1,108 patients with differen...

    Show More
  • Response: Is (creno)balneotherapy a drug, a surgical procedure or a non-pharmacological treatment?
    Thea P Vliet Vlieland

    Dear editor,

    We thank Forestier and Erol for their response on our paper on Eular recommendations for the non-pharmacological core management of hip and knee osteoarthritis (OA). We agree that balneotherapy is a relevant non- pharmacological intervention in hip and knee OA, and has been properly evaluated by means of randomised clinical trials, with the evidence summarized in systematic reviews. The topics to be in...

    Show More
  • Five Factors Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use?
    Sergey V Mooiseev

    Dear Editor,

    In the excellent study recently published in the Annals of the Rheumatic Diseases [1] F.Moosig et al. evaluated the individualized and more aggressive strategy of immunosuppressive treatment in 150 patients with EGPA. Over the last decade we utilized the same approach in our cohort of 117 patients with EGPA. For induction of remission the authors used cyclophosphamide in patients not only with Five Fac...

    Show More
  • Is (creno)balneotherapy a drug, a surgical procedure or a non-pharmacological treatment?
    Romain J FORESTIER

    Dear Editor,

    We appreciate that EULAR is preparing a specific recommendation on non-pharmacological treatment of knee osteoarthritis but we are also very surprised to discover that crenobalneotherapy was not even mentionned in the analysed treatments. Crenobalneotherapy (also called balneotherapy or spa therapy) is a very common treatment for knee osteoarthritis in South and Eastern Europe, Middle Asia, Japan, Sou...

    Show More
  • Visualization of structural damage as a surrogate marker of radiographic progression in patients with rheumatoid arthritis
    Alexander Pfeil

    Dear Editor,

    The article published by Landewe et al. (1) offers novel insights to assess the benefits of new therapeutic strategies in rheumatoid arthritis (RA) which focus more on [the visualization of] structural integrity rather than the inhibition of radiographic progression (1). The authors clearly outline the three major problems of the common superiority study designs:
    I. Differences in progression are...

    Show More
  • Detection of anti-nuclear antibodies. Added-value of solid phase assay?
    Xavier Bossuyt

    Dear Editor,

    Agmon-Levin et al.[1] formulated recommendations for the assessment of anti-nuclear antibodies (ANA). Indirect immunofluorescence (IIF) is considered the reference method for ANA screening, which is in agreement with the ACR position statement[2]. The recommendations are based on current knowledge and expert experience.
    However, as recognized by Meroni and Schur[2], no well-planned studies comp...

    Show More
  • Response to Feldtkeller et al Letter
    Irene van der Horst-Bruinsma

    Dear Editor,

    We would like to thank you for your remarks regarding our manuscript van der Horst-Bruinsma et al Ann Rheum Dis 2013;72:1221- 1224.[1] We do agree that in ankylosing spondylitis, onset is more accurately described by onset of symptoms as opposed to age at diagnosis. Unfortunately, we did not collect the time-of-symptom-onset data in three of the four studies in this analysis. Thus, we used the age at d...

    Show More
  • Authors' response to van der Maas et al
    Kazuki Yoshida

    Dear Editor,

    We would like to thank van der Maas and colleagues for their interest in and useful feedback on our review [1]. They raise several important points. First, regarding the interpretation of the studies included in the review, we focused on studies examining discontinuation of biologic disease modifying antirheumatic drugs (DMARDs) that examined patient outcomes. Thus, we had difficulty in fitting a taperin...

    Show More
  • Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et al.
    Aatke van der Maas

    Dear Editor,

    Yoshida et al present an overview of different designs and 'failure definitions' in biologic discontinuation studies in rheumatoid arthritis (RA).[1] We feel it is a very important review, as the number of discontinuation studies is increasing and therefore awareness of the heterogeneity in these study designs as demonstrated in this review is essential. We have however a few comments. Firstly, one of...

    Show More
  • Response to Dr Bolland's eLetter
    Jean-Yves Reginster

    Dear Editor,

    The work carried out by the authors on calcium and the cardiovascular risk is of primary importance. We thank the authors for questions and comments on the SEKOIA study, safety being a primary concern for us.
    The number of emergent adverse events reported in SEKOIA study was similar in the 3 treatments groups: 85.8%, 87.9% and 86.5% in the SrRan 1g, SrRan 2g and placebo groups as well as the number...

    Show More

Pages